SENS

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

Wall Street analysts forecast SENS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SENS is 15.75 USD with a low forecast of 1.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Senseonics Holdings Inc revenue for the last quarter amounts to 8.10M USD, increased 89.89 % YoY.

Senseonics Holdings Inc. EPS for the last quarter amounts to -8.60 USD, increased 1016.88 % YoY.

Senseonics Holdings Inc (SENS) has 117 emplpoyees as of December 16 2025.

Today SENS has the market capitalization of 277.43M USD.